CareDx Inc (CDNA)vsWaters Corporation (WAT)
CDNA
CareDx Inc
$79.81
-1.68%
HEALTHCARE · Cap: $4.59B
WAT
Waters Corporation
$462.20
-1.85%
HEALTHCARE · Cap: $46.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 1028% more annual revenue ($5.61B vs $497.40M). CDNA leads profitability with a 25.9% profit margin vs 1.8%. CDNA trades at a lower P/E of 36.9x. CDNA earns a higher WallStSmart Score of 60/100 (C).
CDNA
Buy60
out of 100
Grade: C
WAT
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$65.83
Current Price
$79.81
$13.98 discount
Margin of Safety
-19.2%
Fair Value
$276.15
Current Price
$462.20
$186.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.3% year-over-year
Earnings expanding 1067.0% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Revenue surging 120.9% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.0x book value
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
ROE of 0.6% — below average capital efficiency
1.8% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 25.9% and operating margin at 8.5%. Revenue growth of 39.3% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 120.9% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, Price/Book, Return on Equity.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 199.0x leaves little room for execution misses. Thin 1.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CDNA profiles as a growth stock while WAT is a hypergrowth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.38 — expect wider price swings.
WAT is growing revenue faster at 120.9% — sustainability is the question.
WAT generates stronger free cash flow (55M), providing more financial flexibility.
Bottom Line
CDNA scores higher overall (60/100 vs 45/100), backed by strong 25.9% margins and 39.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?